Publications by authors named "Ana Vieira Antao"
Article Synopsis
- Respiratory syncytial virus (RSV) causes severe respiratory infections in young children, highlighting the need for effective vaccines.
- A new vaccine using a rare adenoviral vector (rAd19a) was compared to the more common rAd5, showing promising results in protecting against RSV when given intranasally.
- Intramuscular vaccination with rAd19a led to increased disease severity upon RSV infection, suggesting the importance of local immunity and the need for careful vaccine development to avoid enhanced disease.
Influenza A Virus (IAV) and Respiratory Syncytial Virus (RSV) are both responsible for millions of severe respiratory tract infections every year worldwide. Effective vaccines able to prevent transmission and severe disease, are important measures to reduce the burden for the global health system. Despite the strong systemic immune responses induced upon current parental immunizations, this vaccination strategy fails to promote a robust mucosal immune response.
View Article and Find Full Text PDFArticle Synopsis
- Early-stage breast cancer usually has a good outlook, but if it spreads, especially to the lungs, the prognosis declines; tumor-infiltrating T cells can help control tumors, particularly those with a memory function.
- A study was conducted using a vaccine to create specific T cells in the lungs of mice to prevent and treat lung metastases in breast cancer.
- The vaccine was effective in generating these T cells, reducing lung metastasis growth, and improving survival rates; when used with radiotherapy, it further enhanced outcomes for tumor-bearing mice.
Airway epithelial cells contribute to a variety of lung diseases including allergic asthma, where IL-4 and IL-13 promote activation of the transcription factor STAT6. This leads to goblet cell hyperplasia and the secretion of effector molecules by epithelial cells. However, the specific effect of activated STAT6 in lung epithelial cells is only partially understood.
View Article and Find Full Text PDFSeveral effective SARS-CoV-2 vaccines are currently in use, but effective boosters are needed to maintain or increase immunity due to waning responses and the emergence of novel variants. Here we report that intranasal vaccinations with adenovirus 5 and 19a vectored vaccines following a systemic plasmid DNA or mRNA priming result in systemic and mucosal immunity in mice. In contrast to two intramuscular applications of an mRNA vaccine, intranasal boosts with adenoviral vectors induce high levels of mucosal IgA and lung-resident memory T cells (T); mucosal neutralization of virus variants of concern is also enhanced.
View Article and Find Full Text PDF